AstraZeneca Plc (NASDAQ:AZN) reported fourth-quarter sales of $14.89 billion, up 18% year over year (+19% at constant ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended AstraZeneca's Imfinzi ...

AstraZeneca (AZN) stock rises as its Q4 results which exceeded Street forecasts address concerns over its China investigation ...

Imfinzi has been recommended for approval in the European Union, EU, as monotherapy for the treatment of adults with ...

The company said, “In relation to the illegal drug importation allegations, in January 2025, AstraZeneca (AZN) received a Notice of Transfer to ...

AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.

The boss of AstraZeneca has denied a rift with the Government after axing plans for a £450m vaccine factory in Liverpool ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the immunotherapy be approved to treat adults ...

AstraZeneca shares rose on Thursday after the drugmaker said it could face a fine of up to $4.5 million in China over ...

The pharmaceutical giant's revenue jumped 21 per cent last year despite growing troubles over its presence in China, where it ...

Astrazeneca's revenue jumped 21 per cent last year as the pharmaceutical recorded broad growth across its key businesses.

AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities investigate the company’s former China head. | As AstraZeneca faces an ongoing ...